Lithium chloride ameliorates learning and memory ability and inhibits glycogen synthase kinase-3 beta activity in a mouse model of fragile X syndrome

Neural Regeneration Research

Volumn 6, Issue 31, 2011, Pages 2452-2459

  Chen, Shengqiang ^a,b   Luo, Xuegang ^a   Yang, Quan ^b   Sun, Weiwen ^b   Cao, Kaiyi ^b   Chen, Xi ^b   Huang, Yueling ^c   Dai, Lijun ^c   Yi, Yonghong ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Fmr1 knockout mice; Fragile x syndrome; Glycogen synthase kinase 3 beta; Learning and memory; Lithium chloride; Step down test; Step through test

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME INHIBITION; FRAGILE X SYNDROME; HIPPOCAMPUS; LATENT PERIOD; LEARNING; LEARNING DISORDER; MEMORY; MEMORY DISORDER; MOUSE; NONHUMAN; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 82555172993     PISSN: 16735374     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Pieretti M, Zhang FP, Fu YH, et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell. 1991;66(4):817-822.
2. Garber K, Smith KT, Reines D, et al. Transcription, translation and fragile X syndrome. Curr Opin Genet Dev. 2006;16(3):270-275.
3. Warren ST, Sherman SL. The fragile X syndrome. In: The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill Companies. 2001:1257-1290.
4. Bakker CE, Verheij C, Willemsen R, et al. Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium. Cell. 1994;78:23-33.
5. McBride SM, Choi CH, Wang Y, et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron. 2005;45(5):753-764.
6. Min WW, Yuskaitis CJ, Yan Q, et al. Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology. 2009;56(2): 463-472.
7. Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry. 1999;4(2):117-128.
8. Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001;41:789-813.
9. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003;116 (Pt 7):1175-1186.
10. Shuchang H, Qiao N, Piye N, et al. Protective effects of gastrodia elata on aluminium-chloride-induced learning impairments and alterations of amino acid neurotransmitter release in adult rats. Restor Neurol Neurosci. 2008;26(6):467-473.
11. Berry-Kravis E, Sumis A, Hervey C, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008;29(4):293-302.
12. Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets. 2006;7(11):1421-1434.
13. Qin M, Kang J, Smith CB. A null mutation for Fmr1 in female mice: effects on regional cerebral metabolic rate for glucose and relationship to behavior. Neuroscience. 2005;135(3):999-1009.
14. Bernardet M, Crusio WE. Fmr1 KO mice as a possible model of autistic features. ScientificWorldJournal. 2006;6:1164-1176.
15. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 2004;29(2):95-102.
16. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A. 1996;93(16): 8455-8459.
17. De Sarno P, Li X, Jope RS. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology. 2002;43(7):1158-1164.
18. Yuskaitis CJ, Mines MA, King MK, et al. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem Pharmacol. 2010;79(4): 632-646.
19. Tsaltas E, Kontis D, Boulougouris V, et al. Enhancing effects of chronic lithium on memory in the rat. Behav Brain Res. 2007; 177(1):51-60.
20. Yamaguchi H, Ishiguro K, Uchida T, et al. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol. 1996;92(3):232-241.
21. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J. 2001;359(Pt 1):1-16.
22. Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci. 2007;25(1):59-68.
23. Lucas JJ, Hernández F, Gómez-Ramos P, et al. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001;20(1-2):27-39.
24. Liu SJ, Zhang AH, Li HL, et al. Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J Neurochem. 2003;87(6): 1333-1344.
25. Liu SJ, Zhang JY, Li HL, et al. Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain. J Biol Chem. 2004;279(48):50078-50088.
26. Hernández F, Borrell J, Guaza C, et al. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem. 2002;83(6): 1529-1533.
27. Yu Y, Run X, Liang Z, et al. Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases. J Neurochem. 2009;108(6):1480-1494.
28. Fu ZQ, Yang Y, Song J, et al. LiCl attenuates thapsigargin-induced tau hyperphosphorylation by inhibiting GSK-3β in vivo and in vitro. J Alzheimers Dis. 2010;21(4): 1107-1117.
29. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res. 2007;32(4-5):577-595.
30. Koh SH, Noh MY, Kim SH. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Brain Res. 2008;1188:254-262.
31. Phiel CJ, Wilson CA, Lee VM, et al. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature. 2003;423(6938):435-439.
32. Hooper C, Markevich V, Plattner F, et al. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci. 2007;25(1):81-86.
33. Grimes CA, Jope RS. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem. 2001;78(6):1219-1232.
34. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27(7):370-377.
35. Ma ZE, Sun WW, Li MX, et al. Behavioral observation on Fmr1 knockout mice with audiogenic seizures. Anat Res. 2010;32(6):409-412.
36. Sun WW, Huang YL, Zhang WW, et al. Behavioral comparison on Fmr1 knockout mice at 30 days age in Morris water maze experiment. Anat Res. 2011; 33(1):13-16.
37. Xing Z, Sun WW, Huang YL, et al. Genotype analysis of fmr1 gene knockout mice with polymerase chain reaction. Xiandai Yiyuan. 2009;9(5):12-14.
38. The Ministry of Science and Technology of the People's Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.
39. Ishihara A, Saito H, Ohta H, et al. Basal forebrain lesioned mice exhibit deterioration in memory acquisition process in step through passive avoidance test. Jpn J Pharmacol. 1991; 57(3):329-336.
40. Ahmadi S, Malekmohammadi N, Zarrindast MR. Repeated histamine pretreatment decreased amnesia induced by post-training administration of the drug in a step-down inhibitory avoidance test in mice. Arch Iran Med. 2010;13(3):209-216.
41. Hu S, Chen SM, Li XK, et al. Antitumor effects of chi-shen extract from Salvia miltiorrhiza and Paeoniae radix on human hepatocellular carcinoma cells. Acta Pharmacol Sin. 2007;28(8): 1215-1223.